AAAAAA
Results:
1-20
|
Results: 20
Authors:
Pujade-Lauraine, E
Cure, H
Battista, C
Guastalla, JP
Chiurazzi, B
Fabbro, M
Tubiana-Mathieu, N
Bourgeois, H
Lioure, B
Paraiso, D
Lotz, JP
Citation: E. Pujade-lauraine et al., High dose chemotherapy in ovarian cancer, INT J GYN C, 11, 2001, pp. 64-67
Authors:
Coiffier, B
Guastalla, JP
Pujade-Lauraine, E
Bastit, P
Citation: B. Coiffier et al., Predicting cancer-associated anaemia in patients receiving non-platinum chemotherapy: results of a retrospective survey, EUR J CANC, 37(13), 2001, pp. 1617-1623
Authors:
Duffaud, F
van der Burg, MEL
Namer, M
Vergote, I
Willemse, PHB
Huinink, WT
Guastalla, JP
Nooij, MA
Kerbrat, P
Piccart, M
Tumolo, S
Favalli, G
van der Vange, N
Lacave, AJ
Wils, J
Splinter, TAW
Einhorn, N
Roozendaal, KJ
Rosso, R
Vermorken, JB
Citation: F. Duffaud et al., D-TRP-6-LHRH (Triptorelin) is not effective in ovarian carcinoma: an EORTCgynaecological cancer co-operative group study, ANTI-CANC D, 12(2), 2001, pp. 159-162
Authors:
Fumoleau, P
Chauvin, F
Namer, M
Bugat, P
Tubiana-Hulin, M
Guastalla, JP
Delozier, T
Kerbrat, P
Devaux, Y
Bonneterre, J
Filleul, A
Clavel, M
Citation: P. Fumoleau et al., Intensification of adjuvant chemotherapy: 5-year results of a randomized trial comparing conventional doxorubicin and cyclophosphamide with high-dosemitoxantrone and cyclophosphamide with filgrastim in operable breast cancer with 10 or more involved axillary nodes, J CL ONCOL, 19(3), 2001, pp. 612-620
Authors:
Viens, P
Roche, H
Kerbrat, P
Fumoleau, P
Guastalla, JP
Delozier, T
Citation: P. Viens et al., Epirubicin-docetaxel combination in first-line chemotherapy for patients with metastatic breast cancer - Final results of a dose-finding and efficacystudy, AM J CL ONC, 24(4), 2001, pp. 328-335
Authors:
Wagenaar, HC
Colombo, N
Vergote, I
Hoctin-Boes, G
Zanetta, G
Pecorelli, S
Lacave, AJ
van Hoesel, Q
Cervantes, A
Bolis, G
Namer, M
Lhomme, C
Guastalla, JP
Nooij, MA
Poveda, A
di Palumbo, VS
Vermorken, JB
Citation: Hc. Wagenaar et al., Bleomycin, methotrexate, and CCNU in locally advanced or recurrent, inoperable, squamous-cell carcinoma of the vulva: An EORTC Gynaecological Cancer Cooperative Group study, GYNECOL ONC, 81(3), 2001, pp. 348-354
Authors:
Bremond, A
Bataillard, A
Thomas, L
Achard, JL
Fervers, B
Fondrinier, E
Lansac, J
Bailly, C
Hoffstetter, S
Basuyau, JP
d'Anjou, J
Descamps, P
Farsi, F
Guastalla, JP
Laffargue, F
Rodier, JF
Vincent, P
Pigneux, J
Citation: A. Bremond et al., Standards, Options and Recommendations for the surgical management of carcinoma of the endometrium, B CANCER, 88(2), 2001, pp. 181-198
Authors:
Baum, M
Dowsett, M
Coibion, M
Bianco, AR
Cuzick, J
George, WD
Gray, J
Howell, A
Houghton, J
Williams, N
Sloane, J
Tobias, J
Buzdar, A
Anderson, MD
Jackson, I
Sahmoud, T
Gallagher, J
Webster, A
Gangji, D
Petrakova, K
Konopasek, B
Mares, P
Vodvarka, P
Alcazar, A
Campos, O
Maxwell, A",Goedhals,"Hacking, D
Landers, G
Smith, L
Vorobiof, DA
Werner, ID
Blamey, R
Coleman, R
Grieve, RJ
Hickish, T
Howell, A
Nicholls, JC
Nicholson, S
Raymond, S
Salman, A
Blum, J
Clark, R
Lyss, A
Miletello, G
Sternberg, J
Forbes, J
Coibion, M
Nabholtz, JM
Guastalla, JP
Distler, W
Klijn, JGM
Nagykalnai, T
Nicolucci, A
Bianco, AR
Constenla, M
Nylen, U
Howell, A
Sainsbury, R
Mansel, RE
Goerge, D
Buzdar, AU
Locker, GY
Gallagher, J
Jackson, I
Sahmoud, T
Houghton, J
Williams, N
Nicolucci, A
Pollard, S
Stroner, P
Buyse, M
Margolese, R
Northover, JMA
Citation: M. Baum et al., Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex (TM) and Tamoxifen Alone or in Combination' (ATAC) trial, BR J CANC, 85(3), 2001, pp. 317-324
Authors:
Kerbrat, P
Lhomme, C
Fervers, B
Guastalla, JP
Thomas, L
Tournemaine, N
Basuyau, JP
Cohen-Solal, C
Duvillard, P
Bachelot, T
Ray, I
Voog, E
Dauplat, J
Citation: P. Kerbrat et al., Ovarian cancer, BR J CANC, 84, 2001, pp. 18-23
Authors:
Resbeut, M
Fondrinier, E
Fervers, B
Haie-Meder, C
Bataillard, A
Lhomme, C
Asselain, B
Basuyau, JP
Bremond, A
Castaigne, D
Dubois, JB
Houvenaeghel, G
Lartigau, E
Leblanc, E
Sastre-Garaud, X
Ternier, F
Guastalla, JP
Chauvergne, J
Citation: M. Resbeut et al., Carcinoma of the cervix, BR J CANC, 84, 2001, pp. 24-30
Authors:
Bremond, A
Bataillard, A
Thomas, L
Achard, JL
Fervers, B
Fondrinier, E
Lansac, J
Bailly, C
Hoffstetter, S
Basuyau, JP
d'Anjou, J
Descamps, P
Farsi, F
Guastalla, JP
Laffargue, F
Rodier, JF
Vincent, P
Pigneux, J
Citation: A. Bremond et al., Cancer of the endometrium, BR J CANC, 84, 2001, pp. 31-36
Authors:
Bachelot, T
Ray-Coquard, I
Catimel, G
Ardiet, C
Guastalla, JP
Dumortier, A
Chauvin, F
Droz, JP
Philip, T
Clavel, M
Citation: T. Bachelot et al., Multivariable analysis of prognostic factors for toxicity and survival forpatients enrolled in phase I clinical trials, ANN ONCOL, 11(2), 2000, pp. 151-156
Authors:
Kerbrat, P
Lhomme, C
Fervers, B
Guastalla, JP
Thomas, L
Basuyau, JP
Duvillard, P
Cohen-Solal, C
Dauplat, J
Tournemaine, N
Citation: P. Kerbrat et al., Standards, Options and Recommendations for initial management of patients with a malignant epithelial ovarian tumor, PRESSE MED, 29(38), 2000, pp. 2116-2127
Authors:
Alexandre, J
Bleuzen, P
Bonneterre, J
Sutherland, W
Misset, JL
Guastalla, JP
Viens, P
Faivre, S
Chahine, A
Spielman, M
Bensmaine, A
Marty, M
Mahjoubi, M
Cvitkovic, E
Citation: J. Alexandre et al., Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients, J CL ONCOL, 18(3), 2000, pp. 562-573
Authors:
Nony, P
Guastalla, JP
Rebattu, P
Landais, P
Lievre, M
Bontemps, L
Itti, P
Beaune, J
Andre-Fouet, X
Janier, M
Citation: P. Nony et al., In vivo measurement of myocardial oxidative metabolism and blood flow doesnot show changes in cancer patients undergoing doxorubicin therapy, CANC CHEMOT, 45(5), 2000, pp. 375-380
Authors:
Pujade-Lauraine, E
Guastalla, JP
Vincent, P
Citation: E. Pujade-lauraine et al., Carboplatin in ovarian cancers, B CANCER, 87, 2000, pp. 40-47
Authors:
Mahe, MA
Fumoleau, P
Fabbro, M
Guastalla, JP
Faurous, P
Chauvot, P
Chetanoud, L
Classe, JM
Rouanet, P
Chatal, JF
Citation: Ma. Mahe et al., A phase II study of intraperitoneal radioimmunotherapy with iodine-131-labeled monoclonal antibody OC-125 in patients with residual ovarian carcinoma, CLIN CANC R, 5(10), 1999, pp. 3249S-3253S
Authors:
Bonneterre, J
Spielman, M
Guastalla, JP
Marty, M
Viens, P
Chollet, P
Roche, H
Fumoleau, P
Mauriac, L
Bourgeois, H
Namer, M
Bergerat, JP
Misset, JL
Trandafir, L
Mahjoubi, M
Citation: J. Bonneterre et al., Efficacy and safety of docetaxel (Taxotere (TM)) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience, EUR J CANC, 35(10), 1999, pp. 1431-1439
Authors:
Lhomme, C
Vennin, P
Callet, N
Lesimple, T
Achard, JL
Chauvergne, J
Luporsi, E
Chinet-Charrot, P
Coudert, B
Couette, JE
Guastalla, JP
Lebrun, D
Ispas, S
Blumberg, J
Citation: C. Lhomme et al., A multicenter phase II study with triptorelin (sustained-release LHRH agonist) in advanced or recurrent endometrial carcinoma: A French Anticancer Federation study, GYNECOL ONC, 75(2), 1999, pp. 187-193
Authors:
Haie-Meder, C
Fervers, B
Chauvergne, J
Fondrinier, E
Lhomme, C
Guastalla, JP
Resbeut, M
Citation: C. Haie-meder et al., Standards, options and recommendations: concomitant radiochemotherapy for cancer of the cervix: a critical analysis of the literature and update of SOR, B CANCER, 86(10), 1999, pp. 829-841
Risultati:
1-20
|